Vascular endothelial growth factor-induced tumor angiogenesis and tumorigenicity in relation to metastasis in a HT1080 human fibrosarcoma cell model. 1999

A Mori, and S Arii, and M Furutani, and K Hanaki, and Y Takeda, and T Moriga, and Y Kondo, and M J Gorrin Rivas, and M Imamura
Department of Surgery and Surgical Basic Science, Graduate School of Medicine, Kyoto University, Japan. akr@kuhp.kyoto-u.ac.jp

Although vascular endothelial growth factor (VEGF) is well known to be a potent mitogen for vascular endothelial cells, the role of VEGF in a developmental process of tumor angiogenesis and metastatic potential remains poorly understood. The present study was designed to investigate VEGF-induced vascular formation from a spatiotemporal viewpoint and to analyze VEGF-enhanced metastatic potential using stable clones of HT1080 human fibrosarcoma cells transfected with VEGF cDNA (S) or with vector alone (V). Microangiography revealed massive angiogenesis in the S cell-derived tumors and demonstrated that the angiogenesis occurred not in the tumor itself, but rather around the S cell tumor early after inoculation into the thigh muscles of mice. Thereafter, the angiogenesis extended in and around the tumor. The tumorigenicity of the S cells was higher than the V cells in the subcutaneous (s.c.) space, intraperitoneal space, liver and spleen. However, neither S cells nor V cells metastasized to the liver after an intrasplenic injection. Few apoptotic cells were detected in the S cell tumor, but many apoptotic cells were scattered in the V cell tumor. Our results indicate that VEGF facilitates tumorigenicity in various organs, possibly due to inducing angiogenesis in and around the tumor and preventing tumor cells from undergoing apoptosis, and suggest that VEGF may augment metastatic potential, by accelerating proliferative activity after reaching the target organ. Furthermore, VEGF-induced angiogenesis occurred preferentially around the tumor at an early period of tumor development, followed by neovascularization into the tumor.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008222 Lymphokines Soluble protein factors generated by activated lymphocytes that affect other cells, primarily those involved in cellular immunity. Lymphocyte Mediators,Mediators, Lymphocyte
D008297 Male Males
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D008833 Microcirculation The circulation of the BLOOD through the MICROVASCULAR NETWORK. Microvascular Blood Flow,Microvascular Circulation,Blood Flow, Microvascular,Circulation, Microvascular,Flow, Microvascular Blood,Microvascular Blood Flows,Microvascular Circulations
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009389 Neovascularization, Pathologic A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions. Angiogenesis, Pathologic,Angiogenesis, Pathological,Neovascularization, Pathological,Pathologic Angiogenesis,Pathologic Neovascularization,Pathological Angiogenesis,Pathological Neovascularization
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D005354 Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed) Fibrosarcomas

Related Publications

A Mori, and S Arii, and M Furutani, and K Hanaki, and Y Takeda, and T Moriga, and Y Kondo, and M J Gorrin Rivas, and M Imamura
June 2000, Clinical cancer research : an official journal of the American Association for Cancer Research,
A Mori, and S Arii, and M Furutani, and K Hanaki, and Y Takeda, and T Moriga, and Y Kondo, and M J Gorrin Rivas, and M Imamura
November 1989, The Journal of clinical investigation,
A Mori, and S Arii, and M Furutani, and K Hanaki, and Y Takeda, and T Moriga, and Y Kondo, and M J Gorrin Rivas, and M Imamura
May 2007, Neoplasia (New York, N.Y.),
A Mori, and S Arii, and M Furutani, and K Hanaki, and Y Takeda, and T Moriga, and Y Kondo, and M J Gorrin Rivas, and M Imamura
November 2009, Cancer science,
A Mori, and S Arii, and M Furutani, and K Hanaki, and Y Takeda, and T Moriga, and Y Kondo, and M J Gorrin Rivas, and M Imamura
June 2014, Science and technology of advanced materials,
A Mori, and S Arii, and M Furutani, and K Hanaki, and Y Takeda, and T Moriga, and Y Kondo, and M J Gorrin Rivas, and M Imamura
December 2004, International journal of experimental pathology,
A Mori, and S Arii, and M Furutani, and K Hanaki, and Y Takeda, and T Moriga, and Y Kondo, and M J Gorrin Rivas, and M Imamura
October 2001, Cancer research,
A Mori, and S Arii, and M Furutani, and K Hanaki, and Y Takeda, and T Moriga, and Y Kondo, and M J Gorrin Rivas, and M Imamura
August 1999, British journal of cancer,
A Mori, and S Arii, and M Furutani, and K Hanaki, and Y Takeda, and T Moriga, and Y Kondo, and M J Gorrin Rivas, and M Imamura
September 2000, Cancer research,
A Mori, and S Arii, and M Furutani, and K Hanaki, and Y Takeda, and T Moriga, and Y Kondo, and M J Gorrin Rivas, and M Imamura
January 1996, Cancer research,
Copied contents to your clipboard!